Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
18
Frequently Asked Questions
What is Market Cap of Opus Genetics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Opus Genetics Inc. market cap is $119.22M.
What is the 52-week high for Opus Genetics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Opus Genetics Inc. 52 week high is $2.16 as of October 25, 2025.
What is the 52-week low for Opus Genetics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Opus Genetics Inc. 52 week low is $0.65 as of October 25, 2025.
What is the PE ratio of Opus Genetics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Opus Genetics Inc.’s P/E ratio is -1.13.
What is the Price-to-Book ratio of Opus Genetics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Opus Genetics Inc. P/B ratio is 6.8230.
What is the 50-day moving average of Opus Genetics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Opus Genetics Inc. 50-day moving average is $1.59.
